INVARIANT LLC for CIGNA CORPORATION
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Defense DEF
Monitor pharmacy issues related to H.R 6395 / S. 4049, the National Defense Authorization Act for Fiscal Year 2021.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BENJAMIN KLEIN | — |
| LINDLEY SHERER | — |
Pharmacy PHA
Monitor pharmacy issues related to S. 1895, the Lower Health Care Costs Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BENJAMIN KLEIN | — |
Medicare/Medicaid MMM
Monitor H.R. 7659, the Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BENJAMIN KLEIN | — |
Health Issues HCR
Monitor issues related to telehealth during the COVID-19 emergency; issues related to H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act); issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, the Protecting People from Surprise Medical Bills Act; H.R.2328, the Community Health Investment, Modernization, and Excellence Act of 2019; H.R. 3630, the No Surprises Act; and H.R. 5800, the Ban Surprise Billing Act; issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, the Families First Coronavirus Response Act; P.L. 116-136, the Coronavirus Aid, Response, and Economic Security Act (CARES Act); and H.R. 6379, the Take Responsibility for Workers and Families Act; issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing and transparency and information sharing in the individual and commercial markets; issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts; H.R. 6561/S. 4440, the Improving Social Determinants of Health Act of 2020; the Healthcare, Economic Assistance, Liability, And Schools (HEALS Act); the July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay; and the June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
| Lobbyist | Covered position, as disclosed |
|---|---|
| BENJAMIN KLEIN | — |
| KATHRYN WISE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.